Literature DB >> 6340324

Spread of prostatic cancer to bone.

S C Jacobs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6340324     DOI： 10.1016/0090-4295(83)90147-4

Source DB:  PubMed          Journal:  Urology        ISSN： 0090-4295            Impact factor:   2.649


× No keyword cloud information.
  63 in total

1.  A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.

Authors:  David Ulmert; Reza Kaboteh; Josef J Fox; Caroline Savage; Michael J Evans; Hans Lilja; Per-Anders Abrahamsson; Thomas Björk; Axel Gerdtsson; Anders Bjartell; Peter Gjertsson; Peter Höglund; Milan Lomsky; Mattias Ohlsson; Jens Richter; May Sadik; Michael J Morris; Howard I Scher; Karl Sjöstrand; Alice Yu; Madis Suurküla; Lars Edenbrandt; Steven M Larson
Journal:  Eur Urol       Date:  2012-01-27       Impact factor: 20.096

2.  Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer.

Authors:  Aseem Anand; Michael J Morris; Reza Kaboteh; Lena Båth; May Sadik; Peter Gjertsson; Milan Lomsky; Lars Edenbrandt; David Minarik; Anders Bjartell
Journal:  J Nucl Med       Date:  2015-08-27       Impact factor: 10.057

3.  Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis.

Authors:  Michael O Ports; Ray B Nagle; Gerald D Pond; Anne E Cress
Journal:  Cancer Res       Date:  2009-06-02       Impact factor: 12.701

4.  Combined micro CT and histopathology for evaluation of skeletal metastasis in live animals.

Authors:  Christopher P Geffre; Erika Pond; Gerald D Pond; Isis C Sroka; Jaime M Gard; Bethany A Skovan; William E Meek; Terry H Landowski; Raymond B Nagle; Anne E Cress
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

5.  Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells.

Authors:  Leyre Brizuela; Claire Martin; Pauline Jeannot; Isabelle Ader; Cécile Gstalder; Guillaume Andrieu; Magalie Bocquet; Jean-Michel Laffosse; Anne Gomez-Brouchet; Bernard Malavaud; Roger A Sabbadini; Olivier Cuvillier
Journal:  Mol Oncol       Date:  2014-04-13       Impact factor: 6.603

Review 6.  Spinal cord compression in prostate cancer.

Authors:  J L Osborn; R H Getzenberg; D L Trump
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

7.  Repositioning Dopamine D2 Receptor Agonist Bromocriptine to Enhance Docetaxel Chemotherapy and Treat Bone Metastatic Prostate Cancer.

Authors:  Yang Yang; Kenza Mamouni; Xin Li; Yanhua Chen; Sravan Kavuri; Yuhong Du; Haian Fu; Omer Kucuk; Daqing Wu
Journal:  Mol Cancer Ther       Date:  2018-06-15       Impact factor: 6.261

Review 8.  Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons.

Authors:  Laura Evangelista; Francesco Bertoldo; Francesco Boccardo; Giario Conti; Ilario Menchi; Francesco Mungai; Umberto Ricardi; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-09       Impact factor: 9.236

Review 9.  Zoledronic acid in genitourinary cancer.

Authors:  M A Climent; U Anido; M J Méndez-Vidal; J Puente
Journal:  Clin Transl Oncol       Date:  2013-04-25       Impact factor: 3.405

10.  Overexpression of vascular endothelial growth factor C increases growth and alters the metastatic pattern of orthotopic PC-3 prostate tumors.

Authors:  Johanna Tuomela; Maija Valta; Jani Seppänen; Kati Tarkkonen; H Kalervo Väänänen; Pirkko Härkönen
Journal:  BMC Cancer       Date:  2009-10-12       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.